This can help you and your healthcare provider make adjustments to your treatment plan
Patients with metabolic comorbidities: Autoimmune patients with concurrent insulin resistance, metabolic syndrome, or cardiovascular risk factors benefit doubly, since the GLP-1 addresses both the autoimmune inflammation and the metabolic burden
Storage conditions between injections matter as well
According to Truveta Research presented at ISPOR 2025, side effects were the leading reason patients stopped taking GLP-1 medications, accounting for 28.2% of all discontinuations
Patients on GLP-1 drugs who are experiencing a plateau may also want to talk with their doctor about considering a dose adjustment, medication switch or adding an additional drug
Its once-daily dosing, compared to Ozempic and Wegovys once-weekly dosing, provides flexibility in titration for prescribers and increased adherence for patients who may not be able to keep track of what day of the week they inject